Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

This study is comparing two chemotherapy combinations for women with triple-negative breast cancer (a type that lacks estrogen, progesterone, and HER2 receptors) given before surgery to shrink the tumor — testing whether nab-paclitaxel plus carboplatin works better than nab-paclitaxel plus epirubicin. **You may be eligible if...** - You are a woman between 18 and 70 years old - You have confirmed triple-negative breast cancer by biopsy - Your tumor is larger than 2 cm - You are planning to receive chemotherapy before surgery - Your blood counts, heart function (LVEF ≥ 55%), liver and kidney function are within acceptable levels **You may NOT be eligible if...** - You have previously received any chemotherapy, radiation, or hormone therapy - You have significant heart disease (NYHA grade II or above) - You have a serious active infection or other major illness - You have had another cancer in the past 5 years (except some cured skin cancers) - You are pregnant or breastfeeding - You are participating in another clinical trial Talk to your doctor to see if this trial is right for you.